Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AXSM Axsome Therapeutics Inc
- Stocks
- Healthcare
- NASDAQ: AXSM
Price (delayed)
$108.86
Market cap
$5.36B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$5.77
Enterprise value
$5.27B
Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders for which there are limited treatment options. For the many people
Highlights
AXSM's gross profit has surged by 75% year-on-year and by 12% since the previous quarter
The revenue has soared by 72% YoY and by 12% from the previous quarter
The equity has dropped by 63% year-on-year and by 7% since the previous quarter
The quick ratio has contracted by 37% YoY and by 4.5% from the previous quarter
Key stats
What are the main financial stats of AXSM
Market
Valuations
Earnings
Shares outstanding
49.24M
Market cap
$5.36B
Enterprise value
$5.27B
Price to earnings (P/E)
N/A
Price to book (P/B)
99.78
Price to sales (P/S)
12.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.19
Revenue
$432.16M
Gross profit
$395.36M
Operating income
-$270.27M
Net income
-$278.27M
EBIT
-$270.27M
EBITDA
-$260.37M
Free cash flow
-$118.83M
Per share
Balance sheet
Liquidity
EPS
-$5.77
EPS diluted
-$5.77
Free cash flow per share
-$2.43
Book value per share
$1.09
Revenue per share
$8.84
TBVPS
$11.04
Total assets
$596.67M
Total liabilities
$543.47M
Debt
$209.42M
Equity
$53.21M
Working capital
$250.72M
Debt to equity
3.94
Current ratio
2.03
Quick ratio
1.9
Net debt/EBITDA
0.35
Margins
Efficiency
Dividend
EBITDA margin
-60.2%
Gross margin
91.5%
Net margin
-64.4%
Operating margin
-62.5%
Return on assets
-48.9%
Return on equity
-363.8%
Return on invested capital
-153.9%
Return on capital employed
-76.6%
Return on sales
-62.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AXSM stock price
How has the Axsome Therapeutics stock price performed over time
Intraday
-1.8%
1 week
-3.01%
1 month
11.59%
1 year
43.84%
YTD
28.66%
QTD
-6.66%
Financial performance
How have Axsome Therapeutics's revenue and profit performed over time
Revenue
$432.16M
Gross profit
$395.36M
Operating income
-$270.27M
Net income
-$278.27M
Gross margin
91.5%
Net margin
-64.4%
AXSM's gross profit has surged by 75% year-on-year and by 12% since the previous quarter
The revenue has soared by 72% YoY and by 12% from the previous quarter
AXSM's operating margin is up by 46% year-on-year and by 14% since the previous quarter
Axsome Therapeutics's net margin has increased by 45% YoY and by 14% QoQ
Price vs fundamentals
How does AXSM's price correlate with its fundamentals
Growth
What is Axsome Therapeutics's growth rate over time
Valuation
What is Axsome Therapeutics stock price valuation
P/E
N/A
P/B
99.78
P/S
12.31
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
12.19
The EPS has grown by 10% YoY and by 3.7% from the previous quarter
The P/B is 135% higher than the 5-year quarterly average of 42.4 and 52% higher than the last 4 quarters average of 65.6
The equity has dropped by 63% year-on-year and by 7% since the previous quarter
The revenue has soared by 72% YoY and by 12% from the previous quarter
Efficiency
How efficient is Axsome Therapeutics business performance
The ROE has plunged by 171% YoY and by 26% from the previous quarter
The ROS has grown by 46% YoY and by 14% from the previous quarter
The company's return on invested capital rose by 4.9% QoQ and by 2.3% YoY
AXSM's ROA is up by 5% QoQ and by 3.2% YoY
Dividends
What is AXSM's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AXSM.
Financial health
How did Axsome Therapeutics financials performed over time
Axsome Therapeutics's total assets is 10% more than its total liabilities
The quick ratio has contracted by 37% YoY and by 4.5% from the previous quarter
AXSM's current ratio is down by 37% year-on-year and by 3.8% since the previous quarter
The equity has dropped by 63% year-on-year and by 7% since the previous quarter
The debt to equity has increased by 17% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.